These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1422322)

  • 21. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis.
    Cecchettin M; Bellometti S; Cremonesi G; Solimeno LP; Torri G
    Biomed Pharmacother; 1995; 49(10):465-8. PubMed ID: 8746073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures.
    Anderson FH; Francis RM; Bishop JC; Rawlings DJ
    Age Ageing; 1997 Sep; 26(5):359-65. PubMed ID: 9351480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen.
    Nozaki M; Hashimoto K; Inoue Y; Ogata R; Okuma A; Nakano H
    Int J Gynaecol Obstet; 1998 Jul; 62(1):69-75. PubMed ID: 9722129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.
    Gutteridge DH; Holzherr ML; Retallack RW; Price RI; Will RK; Dhaliwal SS; Faulkner DL; Stewart GO; Stuckey BG; Prince RL; Criddle RA; Drury PJ; Tran L; Bhagat CI; Kent GN; Jamrozik K
    Calcif Tissue Int; 2003 Jul; 73(1):33-43. PubMed ID: 14506952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of ipriflavone on bone loss following a bilateral ovariectomy and menopause: a randomized placebo-controlled study.
    Katase K; Kato T; Hirai Y; Hasumi K; Chen JT
    Calcif Tissue Int; 2001 Aug; 69(2):73-7. PubMed ID: 11683426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass.
    Ohta H; Komukai S; Makita K; Masuzawa T; Nozawa S
    Horm Res; 1999; 51(4):178-83. PubMed ID: 10474019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis.
    Orimo H; Shiraki M; Hayashi Y; Hoshino T; Onaya T; Miyazaki S; Kurosawa H; Nakamura T; Ogawa N
    Calcif Tissue Int; 1994 May; 54(5):370-6. PubMed ID: 8062152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.
    Gonnelli S; Cepollaro C; Montomoli M; Gennari L; Montagnani A; Palmieri R; Gennari C
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):55-61. PubMed ID: 9059558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of a nutritional supplementation on bone health in Chilean elderly subjects with femoral osteoporosis.
    Bunout D; Barrera G; Leiva L; Gattas V; de la Maza MP; Haschke F; Steenhout P; Klassen P; Hager C; Offord E; Hirsch S
    J Am Coll Nutr; 2006 Jun; 25(3):170-7. PubMed ID: 16766774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
    Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
    Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term treatment of Paget's disease of bone with ipriflavone.
    Agnusdei D; Camporeale A; Gonnelli S; Gennari C; Baroni MC; Passeri M
    Bone Miner; 1992 Oct; 19 Suppl 1():S35-42. PubMed ID: 1422319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ipriflavone in the treatment of osteoporosis].
    Makita K; Ohta H
    Nihon Rinsho; 2002 Mar; 60 Suppl 3():359-64. PubMed ID: 11979930
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study.
    Ebeling PR; Wark JD; Yeung S; Poon C; Salehi N; Nicholson GC; Kotowicz MA
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4098-103. PubMed ID: 11549632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women.
    Ravn P; Rix M; Andreassen H; Clemmesen B; Bidstrup M; Gunnes M
    Calcif Tissue Int; 1997 Mar; 60(3):255-60. PubMed ID: 9069162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.
    Delmas PD; Recker RR; Chesnut CH; Skag A; Stakkestad JA; Emkey R; Gilbride J; Schimmer RC; Christiansen C
    Osteoporos Int; 2004 Oct; 15(10):792-8. PubMed ID: 15071723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.